PE-Backed STARLIMS Acquires Labstep

PE-Backed STARLIMS Acquires Labstep

STARLIMS, backed by Francisco Partners, announced on August 22 its acquisition of Labstep for an undisclosed price. According to data captured in the LevinPro HC database, this acquisition represents the 92nd Laboratories, MRI and Dialysis transaction of 2023  Labstep is a modern R&D cloud platform helping customers unlock the power of real-time data. Found in more than 900 universities and more than 65 companies worldwide, Labstep’s Electronic Laboratory Notebook (ELN) platform streamlines laboratory work, delivers real-time data capture and collaboration and enhances data integrity.  STARLIMS provides enterprise informatics solutions and is committed to providing quality... Read More »
Abbott Acquires Cardiovascular Systems for $890 Million

Abbott Acquires Cardiovascular Systems for $890 Million

Abbott is expanding its cardiovascular device portfolio with its acquisition of Cardiovascular Systems. Under terms of the agreement, Cardiovascular Systems’ stockholders will receive $20 per common share at a total expected equity value of approximately $890 million. J.P. Morgan Securities LLC served as the financial advisor to Cardiovascular Systems. The transaction is expected to be neutral to Abbott’s 2023 ongoing earnings per share guidance. Cardiovascular Systems is a medical device company focused on the development and commercialization of solutions for treating complex peripheral vascular disease and coronary artery disease. Abbott manufactures and sells healthcare... Read More »
Alere Spins Off Assets to Aid Abbott Merger

Alere Spins Off Assets to Aid Abbott Merger

Since February 2016, we’ve followed the testy merger between Abbott (NYSE: ABT) and Alere’s (NYSE: ALR) agreement to merge, followed by the respective lawsuits, and then the price renegotiation. Half way through 2017, the $5.3 billion deal is getting closer to completion, as Alere spins off some assets to comply with antitrust regulations. The first to go is Alere’s Triage® MeterPro cardiovascular (CV) and toxicology assets (“Triage business”), together with the B-type Naturietic Peptide (BNP) assay business run on Beckman Coulter analyzers (“BNP business”). The buyer is  Quidel Corporation (NASDAQ: QDEL), which will acquire the Triage business, including real estate for the San... Read More »

Abbott and Alere: The Wedding Is Back On!

It seems so long ago. Back in February 2016,  Abbott (NYSE: ABT) and Alere Inc. (NYSE: ALR) announced their $5.8 billion deal. Abbott’s board okay’ed paying $56 per common share of Alere, representing a 51% premium to the company’s close on January 28, 2016. Abbott also assumed $2.6 billion of debt. The combination was expected to create a premier point-of-care testing business and to strengthen Abbott’s diagnostics presence. Alere’s main business is its point-of-care diagnostics and services, which are focused on the areas of infectious disease, cardio-metabolic disease, and toxicology. Point of care testing is a $5.5 billion segment, and one... Read More »

Abbott to Alere: It’s You, Not Me

The party’s about over for the $5.8 billion Abbott (NYSE: ABT) acquisition of Alere Inc. (NYSE: ALR). Everything was bright and rosy when Abbott agreed to pay $56.00 per share for the point-of-care diagnostics and services company. Now, the $177 million termination fee Abbott faces to get out of the deal looks pretty cheap. In April, Abbott reportedly offered Alere $50 million to terminate the deal, but got no takers. The trouble began almost immediately. The day of the announcement, February 1, Alere’s stock price shot up nearly 46%, to $54.11. But later that month,  it announced would delay filing its 2015 financial results with securities regulators due to revenue recognition... Read More »